Equities research analysts expect CVS Health Corp (NYSE:CVS) to post earnings of $1.89 per share for the current quarter, according to Zacks Investment Research. Eighteen analysts have made estimates for CVS Health’s earnings, with estimates ranging from $1.88 to $1.92. CVS Health reported earnings per share of $1.71 in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.5%. The firm is scheduled to issue its next earnings results on Thursday, February 8th.

According to Zacks, analysts expect that CVS Health will report full year earnings of $5.89 per share for the current financial year, with EPS estimates ranging from $5.87 to $5.92. For the next year, analysts expect that the business will report earnings of $6.45 per share, with EPS estimates ranging from $6.13 to $7.16. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow CVS Health.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same period in the previous year, the firm earned $1.64 earnings per share. CVS Health’s revenue for the quarter was up 3.5% on a year-over-year basis.

Several equities research analysts have issued reports on the stock. Vetr downgraded shares of CVS Health from a “hold” rating to a “sell” rating and set a $76.66 price objective for the company. in a research note on Tuesday. ValuEngine downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. SunTrust Banks upped their target price on shares of CVS Health to $90.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Leerink Swann upped their target price on shares of CVS Health from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, January 8th. Finally, Morgan Stanley upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price for the company in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $86.63.

CVS Health (CVS) traded up $0.66 on Wednesday, reaching $79.44. 8,437,101 shares of the company’s stock traded hands, compared to its average volume of 8,990,430. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.72. The stock has a market capitalization of $80,050.00, a P/E ratio of 16.41, a P/E/G ratio of 1.25 and a beta of 0.90.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $2.00 annualized dividend and a yield of 2.52%. CVS Health’s dividend payout ratio is presently 41.32%.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at $1,166,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.61% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Fieldpoint Private Securities LLC raised its holdings in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the period. Wealthcare Advisory Partners LLC raised its holdings in shares of CVS Health by 330.3% during the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares during the period. Arcadia Investment Management Corp MI raised its holdings in shares of CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in shares of CVS Health during the second quarter worth $119,000. Finally, Gemmer Asset Management LLC raised its holdings in shares of CVS Health by 15.3% during the second quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares during the period. 81.69% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate CVS Health Corp (CVS) to Announce $1.89 Earnings Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/analysts-anticipate-cvs-health-corp-cvs-to-announce-1-89-earnings-per-share.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.